Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002 · see citing works

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610 · see citing works

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · see citing works

<i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473 · see citing works

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468 · see citing works

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360 · see citing works

Heat Shock Protein 90 as a Drug Target: Some Like It Hot

Banerji, U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0132 · Cited by 265 · see citing works

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211 · see citing works

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

Sessa, C., Shapiro, G. I., Bhalla, K. N., Britten, C. D., Jacks, K. S., Mita, M. M., Papadimitrakopoulou, V., Pluard, T., Samuel, T. A., Akimov, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3404 · Cited by 163 · see citing works

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131 · see citing works

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Johnson, M. L., Yu, H. A., Hart, E. M., Weitner, B. B., RADEMAKER, A. W., Patel, J. D., Kris, M. G., & Riely, G. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7328 · Cited by 129 · see citing works

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

Felip, E., Barlési, F., Besse, B., Chu, Q. S.-C., Gandhi, L., Kim, S., Carcereny, E., Sequist, L. V. D., Brunsvig, P. F., CHOUAID, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.131 · Cited by 96 · see citing works

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Jorge, S. E., Lucena-Araujo, A. R., Yasuda, H., Piotrowska, Z., Oxnard, G. R., Rangachari, D., Huberman, M. S., Sequist, L. V. D., Kobayashi, S. S., & Costa, D. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1541 · Cited by 60 · see citing works

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

Doebele, R. C., Riely, G. J., Spira, A. I., Horn, L., Piotrowska, Z., Costa, D. B., Neal, J. W., Zhang, S., Reichmann, W. M., Kerstein, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9015 · Cited by 35 · see citing works

Reversible Nyctalopia and Retinopathy in a Patient With Metastatic Cancer Treated With Anti–Heat Shock Protein 90 Therapy

Munk, M. R., Fernandes, J. K., Mets, M. B., Patel, J. D., Johnson, M. L., & Jampol, L. M. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.409 · Cited by 9 · see citing works

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 380 · see citing works

Discovering Anti-Cancer Drugs via Computational Methods

Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y.-H., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 310 · see citing works

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 127 · see citing works

An update on the status of HSP90 inhibitors in cancer clinical trials

Rastogi, S., Joshi, A., Sato, N., Lee, S., Lee, M.-J., Trepel, J. B., & Neckers, L. (2024) · Cell Stress and Chaperones · doi:10.1016/j.cstres.2024.05.005 · Cited by 123 · see citing works

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works

Heat shock protein 90: biological functions, diseases, and therapeutic targets

Wei, H., Zhang, Y., Jia, Y., Chen, X., Niu, T., Chatterjee, A., He, P., & Hou, G. (2024) · MedComm · doi:10.1002/mco2.470 · Cited by 110 · see citing works

Targeting EGFR Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates

Meador, C. B., Sequist, L. V. D., & Piotrowska, Z. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0226 · Cited by 104 · see citing works

Tyrosine Kinase Receptors in Oncology

Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 100 · see citing works

Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review

Burnett, H. F., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P. J., & Li, T. M. W. Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247620 · Cited by 90 · see citing works

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors

Qin, Y., Jian, H., Tong, X., Wu, X., Wang, F., Shao, Y. W., & Zhao, X. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12710 · Cited by 66 · see citing works

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 66 · see citing works

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., Wang, L., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00372-6 · Cited by 62 · see citing works

Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer

Wang, H., Huang, H., Wang, L., Liu, Y., Wang, M., Zhao, S., Lu, G., & Kang, X. (2021) · Aging · doi:10.18632/aging.103556 · Cited by 59 · see citing works

Inhibiting Heat Shock Protein 90 Protects Nucleus Pulposus-Derived Stem/Progenitor Cells From Compression-Induced Necroptosis and Apoptosis

Hu, B., Zhang, S., Liu, W., Wang, P., Chen, S., Lv, X., Shi, D., Ma, K., Wang, B., Wu, Y., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00685 · Cited by 48 · see citing works

Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance

Rahman, M. M., Islam, M. R., Rahman, F., Rahaman, M. S., Khan, M. S., Abrar, S., Ray, T. K., Uddin, M. B., Kali, M. S. K., Dua, K., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9080335 · Cited by 44 · see citing works

EGFR exon 20 insertion mutations in non-small cell lung cancer

Wang, F., Li, C., Wu, Q., & Lu, H. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.10 · Cited by 40 · see citing works

EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies

Bai, Q., Wang, J., & Zhou, X. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102605 · Cited by 38 · see citing works

Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I

Upadhya, A., Yadav, K. S., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825377 · Cited by 37 · see citing works

Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes

Kwon, C. S., Lin, H. M., Crossland, V., Churchill, E. N., Curran, E. J., Forsythe, A., Tomaras, D., & Ou, S. I. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2083326 · Cited by 36 · see citing works

The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions

Zhang, T., Lv, Q., & Jin, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189137 · Cited by 34 · see citing works

Recent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery

Razia, I. T., Kanwal, A., Riaz, H. F., Malik, A., Ahsan, M., Khan, M. S., Raza, A., Sabir, S., Sajid, Z., Khan, M. F., et al. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266258467231107102643 · Cited by 26 · see citing works

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells

Park, K., Hong, Y. S., Choi, J., Yoon, S., Kang, J., Kim, D., Lee, K. P., Im, H.-S., Lee, C. H., Seo, S., et al. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.12.259 · Cited by 26 · see citing works

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 26 · see citing works

The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives

Dorta, M., de Miguel, M., Amor-Carro, Ó., Calderón, J. M., González-Ortega, M., & Rodríguez‐Abreu, D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102671 · Cited by 25 · see citing works

Recent advances in HSP90 inhibitors as targeted cancer therapy: Chemical scaffolds, isoform selectivity, and clinical progress

Goel, B., Jaiswal, S., & Tripathi, N. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108782 · Cited by 22 · see citing works

Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective

Workman, P. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-40204-4_11 · Cited by 22 · see citing works

A hierarchical attention network integrating multi-scale relationship for drug response prediction

Wang, X., Wen, Y., Zhang, Y., Dai, C., Yang, Y., Bo, X., He, S., & Peng, S. (2024) · Information Fusion · doi:10.1016/j.inffus.2024.102485 · Cited by 21 · see citing works

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer

Lombardi, R., Sonego, M., Pucci, B., Addi, L., Iannelli, F., Capone, F., Alfano, L., Roca, M. S., Milone, M. R., Moccia, T., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12883 · Cited by 20 · see citing works

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma

Pacini, L., Cabal, V. N., Hermsen, M. A. J. A., & Huang, P. H. (2022) · Cancers · doi:10.3390/cancers14020394 · Cited by 20 · see citing works

Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma

Siebert, C., Ciato, D., Murakami, M., Frei‐Stuber, L., Perez‐Rivas, L. G., Garcia, J. L. M., Nölting, S., Maurer, J., Feuchtinger, A., Walch, A. K., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00487 · Cited by 19 · see citing works

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

Riess, J. W., Reckamp, K. L., Frankel, P. H., Longmate, J., Kelly, K. A., Gandara, D. R., Weipert, C. M., Raymond, V. M., Keer, H. N., Mack, P. C., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.05.001 · Cited by 19 · see citing works

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs

Watanabe, S., Goto, Y., Yasuda, H., Kohno, T., Motoi, N., Ohe, Y., Nishikawa, H., Kobayashi, S. S., Kuwano, K., & Togashi, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13839 · Cited by 17 · see citing works

Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro

Epp-Ducharme, B., Dunne, M., Fan, L., Evans, J. C., Ahmed, L., Bannigan, P., & Allen, C. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-90585-w · Cited by 18 · see citing works

HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells

Mouratidis, P., & ter Haar, G. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1983036 · Cited by 17 · see citing works

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments

Zwierenga, F., van Veggel, B. A. M. H., van den Berg, A., Groen, H. J. M., Zhang, L., Groves, M. R., Kok, K., Smit, E. F., Hiltermann, T. J. N., Langen, A. J. D., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102628 · Cited by 17 · see citing works

Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo

Liu, Y.-M., Tu, H., Wu, C.-H., Lai, M.-J., Yu, S.-C., Chao, M., Wu, Y.-W., Teng, C., Pan, S., & Liou, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113428 · Cited by 16 · see citing works

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines

Codony‐Servat, J., Viteri, S., Codony, C., Ito, M., Bracht, J. W. P., Berenguer, J., CHAIB-OUKADOUR, I., Molina‐Vila, M. Á., Karachaliou, N., & Rosell, R. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.22 · Cited by 15 · see citing works

Therapy resistance: Modulating evolutionarily conserved heat shock protein machinery in cancer

Skrabalak, I., Rajtak, A., Małachowska, B., Skrzypczak, N., Skalina, K. A., Guha, C., Kotarski, J., & Okła, K. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217571 · Cited by 14 · see citing works

HSP90: A promising target for NSCLC treatments

Zhu, Y., & Dai, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176387 · Cited by 14 · see citing works

Assessment of Hsp90β-selective inhibitor safety and on-target effects

Reynolds, T. S., Mishra, S. J., & Blagg, B. S. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-86647-y · Cited by 14 · see citing works

Medium-Throughput Detection of Hsp90/Cdc37 Protein–Protein Interaction Inhibitors Using a Split Renilla Luciferase-Based Assay

Siddiqui, F. A., Parkkola, H., Manoharan, G. B., & Abankwa, D. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219884033 · Cited by 13 · see citing works

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations

Shi, C., Xing, R., Li, M., Feng, J., Sun, R., Wei, B., Guo, Y., Ma, J., & Wang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949304 · Cited by 15 · see citing works

Modified bone marrow mesenchymal stem cells derived exosomes loaded with MiRNA ameliorates non‐small cell lung cancer

Yang, M., Zhou, W., Han, X. L., Xu, M., Wang, Z., Shi, M., Shi, Y., & Yu, Y. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70115 · Cited by 12 · see citing works

Polydatin-Mediated Inhibition of HSP90α Disrupts NLRP3 Complexes and Alleviates Acute Pancreatitis

Yang, J., Jiao, C., Liu, N., Liu, W., Wang, Y., Pan, Y., Kong, L., Guo, W., & Xu, Q. (2024) · Research · doi:10.34133/research.0551 · Cited by 13 · see citing works

Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre

Suryavanshi, M., Jaipuria, J., Mattoo, S., Dhandha, S., & Khatri, M. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.06.003 · Cited by 13 · see citing works

Prediction of Prognosis and Chemotherapeutic Sensitivity Based on Cuproptosis-Associated lncRNAs in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma

Zhou, J., Xu, L., Zhou, H. H., Wang, J., & Xing, X. (2023) · Genes · doi:10.3390/genes14071381 · Cited by 10 · see citing works

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer

Pan, B., Liang, J., Shi, H., Rao, K., Guo, W., & Zhan, C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15127 · Cited by 9 · see citing works

Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients

Scodes, S., & Cappuzzo, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1746646 · Cited by 10 · see citing works

Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

Xie, C., Kong, J., Miao, F., Wang, X., & Sheng, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13487 · Cited by 9 · see citing works

Design and Synthesis of Novel 6,7‐Dihydrobenzo[d]isoxazol‐4(5H)‐one Derivatives Bearing 1,2,3‐Triazole Moiety as Potential Hsp90 Inhibitors and their Evaluation as Antiproliferative Agents

Varabyeva, N. A., Salnikova, D. I., Krymov, S. K., Bogdanov, F. B., Shchekotikhin, A. E., Puzanau, R. M., Sorokin, D. V., Лахвич, Ф. А., Scherbakov, A. M., & Piven, Y. A. (2024) · ChemistrySelect · doi:10.1002/slct.202304812 · Cited by 7 · see citing works

Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming

Liu, H., Qin, J., & Qian, X. (2024) · Cancer Control · doi:10.1177/10732748241292782 · Cited by 7 · see citing works

Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report

Ma, Y., Liu, H., Zhang, M., Liu, B., Ding, Q., Zhang, L., Guo, L., & Liu, M. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-321 · Cited by 6 · see citing works

Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns

Bai, R., Chen, X., Song, W., Tian, H., & Cui, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03840-y · Cited by 7 · see citing works

Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment

Bílek, O., Holánek, M., Berkovcová, J., Horký, O., Kazda, T., Čoupková, H., Špelda, S., Kristková, L., Zvaríková, M., Podhorec, J., et al. (2019) · Klinicka onkologie · doi:10.14735/amko20193s6 · Cited by 7 · see citing works

Current paradigm of EGFR in non-small cell lung cancer: A long way forward

Miyamura, B. V., Mambetsariev, I., Fricke, J., Arias-Romero, J., Cadman, K., Shrestha, S., Pisick, E. P., Nguyen, D., Malhotra, J. D., Reyes, A., et al. (2025) · Med · doi:10.1016/j.medj.2025.100803 · Cited by 5 · see citing works

Targeting exon 20 insertion mutations in lung cancer

Yang, Y., & Wang, Y. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000919 · Cited by 5 · see citing works

CADD Approaches in Anticancer Drug Discovery

Biswas, A., & Jayaprakash, V. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-1316-9_12 · Cited by 5 · see citing works

Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report

Zhang, Y., Wang, H., Wang, X., Li, S., & Fang, H. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.008 · Cited by 5 · see citing works

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].

Yang, X., & Zhao, J. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.103.01 · Cited by 4 · see citing works

Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients

Garzón‐Ibáñez, M., Reyes, R., Molina‐Vila, M. Á., & Sullivan, I. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03899-w · Cited by 4 · see citing works

Effects of a combined treatment regimen consisting of Hsp90 inhibitor DS-2248 and radiation in vitro and in a tumor mouse model

Kondo, T., Shibamoto, Y., Kawai, T., SUGIE, C., Wang, Z., Nakamura, K., Murai, T., Manabe, Y., Nakashima, M., & Matsuo, M. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-71 · Cited by 4 · see citing works

Novel N -(4,5,6,7-tetrahydrobenzisoxazol-4-yl)amides as HSP90 inhibitors: design, synthesis and biological evaluation

Varabyeva, N. A., Scherbakov, A. M., Salnikova, D. I., Sorokin, D. V., Khamidullina, A. I., Mikhaylova, A. L., Paulovich, D. I., Лахвич, Ф. А., & Piven, Y. A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00904e · Cited by 3 · see citing works

Potential benefits of combined treatment with Hsp90 inhibitor AUY922 and cisplatin for overcoming drug resistance in nasopharyngeal carcinoma

Cho, W. C. S. (2025) · American Journal of Cancer Research · doi:10.62347/osgo7209 · Cited by 3 · see citing works

Screening Novel Drug Candidates for Kidney Renal Clear Cell Carcinoma Treatment: A Study on Differentially Expressed Genes through the Connectivity Map Database

Gao, B., Wang, L., Zhang, N., Han, M., Zhang, Y., Liu, H., Sun, D., & Liu, Y. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000518437 · Cited by 3 · see citing works

New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations

Gil‐Sierra, M. D., Briceño-Casado, M. D. P., & Cristina, M.-R. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231162545 · Cited by 2 · see citing works

Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study

Liu, G., Nyaw, S. F., Mok, T. S. K., Curcio, H., Cortot, A. B., Kam, T. Y., Descourt, R., Chik, Y. K. J., Cheema, P. K., Gwinnutt, J. M., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70369 · Cited by 2 · see citing works

Nature-Based Computing Bioinformatics Approaches in Drug Discovery Against Promising Molecular Targets Carbonic Anhydrases and Serine/Threonine Kinases for Cancer Treatment

Peerzada, M. N., Rizvi, M. A., Ajeesh Kumar, K. K., Sahu, A., & Verma, S. M. (2022) · Studies in computational intelligence · doi:10.1007/978-981-19-6379-7_16 · Cited by 2 · see citing works

EGFR exon 20 insertion in non-small cell lung cancer

Panda, G. S., Noronha, V., Shetty, O. A., Yadav, S. C., Kumar, R., Patil, V., Chandrani, P., Janu, A., Mahajan, A., Chougule, A., et al. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_77_22 · Cited by 2 · see citing works

Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphoma

Zhu, S., Zhao, Y. M., Xing, C., Guo, W., Huang, Z., Zhang, H., Yin, L., Ruan, X., Li, H., Cheng, Z., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18836 · Cited by 1 · see citing works

Protein post-translational modifications in CAR-T cells: Novel strategies to amplify antitumor efficacy via epigenetic and metabolic circuitry

Li, J., Sun, H., Li, W., Zhao, N., Guo, Z., Chen, J., & Yu, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104968 · Cited by 1 · see citing works

[Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer].

Wang, Y., & Chu, T. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.06 · Cited by 1 · see citing works

Correlation of EGFR G873R mutation with prognosis of docetaxel in non-small cell lung cancer

Tian, Y., Zhao, X., Li, P., Lü, M., & Tian, H. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1505 · Cited by 1 · see citing works

[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].

Zhou, W., Zhang, W., & Han, B. (2020) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2020.02.07

Naturbasierte bioinformatische Ansätze in der Arzneimittelforschung gegen vielversprechende molekulare Ziele – Carbonanhydrasen und Serin/Threonin-Kinasen zur Krebsbehandlung

Peerzada, M. N., Rizvi, M. A., Ajeeshkumar, K. K., Sahu, A., & Verma, S. M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7808-3_16

The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis

Liu, K., Li, H., Tan, Q.-Q., Jiang, T., Peng, K., Chen, H.-J., Zhou, Q., Zhang, X., Zheng, Z., Chen, S., et al. (2025) · Science Progress · doi:10.1177/00368504251325406

Synthesis of 3-(5-isopropyl-2,4-dimethoxyphenyl)-4-methoxybenzo[d]isoxazole-5-amine and its application for the preparation of new Hsp90 inhibitors

Varabyeva, N. A., Paulovich, D. I., Chukarina, T. V., Огурцова, С. Э., Piven, Y. A., & Лахвич, Ф. А. (2025) · Proceedings of the National Academy of Sciences of Belarus Chemical Series · doi:10.29235/1561-8331-2025-61-3-218-226

HIFs: The central drivers of tumors and their role as molecular switches in targeted therapy?

Peng, Y., Che, Y., Zhao, Y., Wang, Z., Pei, Z., Hu, Y., Yin, Y., Pan, X., Hu, X., Wei, M., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.040

Isoform-selective HSP90 inhibition as a precision therapeutic strategy for neurodegenerative and metabolic diseases

Alanazi, S. M., Al‐kuraishy, H. M., Alexiou, A. T., Papadakis, M., Faheem, S. A., & Batiha, G. E. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111834

Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice

Li, C., Yin, X., Zhou, S., Wen, J., Yu, J., & Meng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02689-2

BindingDB Entry 50013799: Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.

BindingDB (2022) · UC San Diego · doi:10.7270/q2dv1pn4

OA 12.02 Final Results of a Phase 2 Study of the hsp90 Inhibitor Luminespib (AUY922) in NSCLC Patients Harboring EGFR Exon 20 Insertions

Piotrowska, Z., Costa, D. B., Huberman, M. S., Oxnard, G. R., Gainor, J. F., Heist, R. S., Lennes, I. T., Muzikansky, A., Shaw, A. T., Azzoli, C. G., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.395 · Cited by 3 · see citing works

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Jorge, S. E., Lucena-Araujo, A. R., Yasuda, H., Piotrowska, Z., Oxnard, G. R., Rangachari, D., Huberman, M. S., Sequist, L. V. D., Kobayashi, S. S., & Costa, D. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1541 · Cited by 60 · see citing works

Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.

Piotrowska, Z., Costa, D. B., Huberman, M. S., Oxnard, G. R., Gainor, J. F., Heist, R. S., Muzikansky, A., Shaw, A. T., Niederst, M. J., Fulton, L. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8015 · Cited by 15 · see citing works

Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer

van Veggel, B. A. M. H., van der Wekken, A. J., Hashemi, S. M. S., Cornelissen, R., Monkhorst, K., Heideman, D. A. M., Radonic, T. R., Smit, E. F., Schuuring, E. M. D., & de Langen, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy292.072 · Cited by 4 · see citing works

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

Riess, J. W., Reckamp, K. L., Frankel, P. H., Longmate, J., Kelly, K. A., Gandara, D. R., Weipert, C. M., Raymond, V. M., Keer, H. N., Mack, P. C., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.05.001 · Cited by 19 · see citing works